AC Immune Cash Flow | StatInvestor

Health Care & Life Sciences » Biotechnology | AC Immune

AC Immune S.A. | Cash Flow

Fiscal year is January-December. All values USD Thousands.

2014

2015

2016

2017

2018

Net Income before Extraordinaries

11,736.80

21,051.40

7,202.80

26,833.30

52,061.90

Depreciation, Depletion & Amortization

325.50

298.10

282.20

589.30

982

Other Funds

57.10

4,189.40

Funds from Operations

12,460.00

19,878.90

8,824.90

20,071.90

46,890.50

Changes in Working Capital

31,712.50

25,904.60

3,093.90

2,375.40

1,851.50

Net Operating Cash Flow

19,252.50

45,783.50

5,731.00

22,447.30

45,039

Capital Expenditures

139.80

253.40

912.50

1,830.80

Net Investing Cash Flow

143.10

253.40

912.50

1,871.50

Issuance/Reduction of Debt, Net

203.20

Net Financing Cash Flow

10,706.60

28,848.90

79,976.30

275.30

Net Change in Cash

8,679.10

76,038.60

76,827.60

28,278.00

Free Cash Flow

19,392.40

45,530.10

6,643.60

24,278.10

Change in Capital Stock

10,706.60

28,791.80

79,976.30

72.10

Exchange Rate Effect

9.80

1,659.60

3,494.80

4,234.60

Other Uses

3.30

40.60

About AC Immune

View Profile

Address	EPFL Innovation Park Lausanne Basel-Landschaft (Basle Country) 1015 Switzerland
Employees	-
Website	http://www.acimmune.com
Updated	07/08/2019
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, and Andrea Pfeifer on February 13, 2003 and is headquartered in Lausanne, Switzerland.